Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye
NCT ID: NCT00037661
Last Updated: 2015-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
222 participants
INTERVENTIONAL
2002-04-30
2003-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease
NCT00403715
A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease
NCT00679718
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease
NCT00404131
A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution
NCT00680108
A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants
NCT05992922
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
INS365 Ophthalmic Solution
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* had intermittent or regular artificial tear use within past 3 months
Exclusion Criteria
* had punctal occlusion or cauterization within last 3 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
03-108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.